FAU researchers and collaborators provide the most updated guidance to health care providers and urge how widespread vaccination with these boosters can now avoid the specter of future and more lethal variants becoming a reality.
UCLA leads CDC-funded study on effectiveness of vaccines, boosters in ‘next phase’ of COVID
The David Geffen School of Medicine at UCLA has been awarded a $13.6 million grant from the Centers for Disease Control and Prevention to continue to study the effectiveness of COVID-19 vaccines and the long-term impact of infection among U.S. health care workers. The new yearlong grant project follows the 2020–21 Preventing Emerging Infections Through Vaccine Effectiveness Testing study, or PREVENT I, which was among the first to demonstrate the real-world benefit of mRNA vaccines in preventing symptomatic infection following their authorization by the Food and Drug Administration.
Study Examines Data Transparency, Health Equity in U.S. COVID-19 Response
State governments varied widely in COVID-19 pandemic mitigation measures and how they addressed immediate and long-standing health disparities and associated inequities.
Newer COVID-19 Subvariants Are Less Vulnerable to Immunity Induced by Vaccination and Previous Infection, Researchers Find
In a letter published in the New England Journal of Medicine, physician-scientists report that the three Omicron subvariants currently dominant in the United States – officially known as subvariants BA.2.12.1, BA.4, and BA.5 – substantially escape neutralizing antibodies induced by both vaccination and previous infection.
FAU Expert Answers Questions about Delta Variant, Vaccines and Public Safety
Florida Atlantic University’s Joanna Drowos, D.O., M.P.H., M.B.A., Schmidt College of Medicine, provides answers to some of the most frequently asked questions regarding the COVID-19 Delta variant, vaccines and public safety measures.
Penn-led Consortium Identifies More Genetic Markers for Inherited Testicular Cancer
A meta-analysis of nearly 200,000 men revealed 22 new genetic locations that could be susceptible to inherited testicular germ cell tumors.
@UBuffalo biochemist @SurteesJennifer warns that the delta variant is particularly an issue for those individuals who are not vaccinated or are under vaccinated (i.e. 1 shot).
Expert: Jennifer Surtees, PhD, associate professor of biochemistry in the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo. Surtees and her colleagues at UB’s New York State Center of Excellence in Bioinformatics and Life Sciences have…
Story Tips from Johns Hopkins Experts on COVID-19
Coping with childhood anxiety amid returning to the classroom; new global tracker measures pandemic’s impact on education worldwide; Covid-19 drives innovation and evolution in patient care…
Rutgers Develops Rapid Test to Detect New Emerging Coronavirus Variants
Rutgers researchers have designed a new rapid test that can detect all three of the rapidly spreading variants of the coronavirus in a little over one hour – much shorter than the three to five days required by current tests, which can also be more technically difficult and expensive to perform.
Monoclonal Antibody “Cocktail” Blocks COVID-19 Variants: Study
A monoclonal antibody “cocktail” developed at Vanderbilt University Medical Center (VUMC) to neutralize the COVID-19 virus is effective against all known strains, or variants, of the virus, according to a report published in the journal Nature Medicine.
New evidence COVID-19 antibodies, vaccines less effective against variants
New research from Washington University School of Medicine in St. Louis has found that new variants of the virus that causes COVID-19 can evade antibodies that work against the original form of the virus that sparked the pandemic, potentially undermining the effectiveness of vaccines and antibody-based drugs now being used to prevent or treat COVID-19.
How SARS-CoV-2 Mutates to Escape Antibody Binding
A scientific detective story starting with a single patient in Pittsburgh unearths how the SARS-CoV-2 virus mutates to create new variants, including the UK strain B.1.1.7, and escapes neutralizing antibodies.